Kelli Whitlock Burton is a reporter for Medscape, covering a wide range of medical and health topics. With a focus on research and clinical developments, Kelli provides in-depth analysis and reporting on issues related to neurology, mental health, and general healthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kelli Whitlock Burton's coverage predominantly revolves around healthcare, pharmaceuticals and scientific research. Her articles are data-driven, focusing on various health conditions including traumatic brain injury, cognitive function, dementia, ultrasprocessed foods and more. If you are a researcher or professional with access to new data or insights related to these topics, providing relevant statistics and evidence-based information could be compelling for her coverage.
Given the extensive use of data in Kelli's articles, she may respond well to pitches that include recent studies or statistical analysis supporting healthcare-related claims. Providing unique datasets or access to experts who can interpret complex medical findings would likely interest her.
Although there is no specific geographic focus mentioned for Kelli's work, it seems that she covers global health issues without specific regional limitations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Disappointing phase 3 trial results of a drug approved for the treatment of amyotrophic lateral sclerosis (ALS) may prompt the manufacturer to voluntarily pull it from the market, the company announced today.
By: Kelli Whitlock Burton
May 1, 2024 – You shouldn’t draw major conclusions about the safety of marijuana amid the recent announcement that federal regulators may reclassify the drug, experts are cautioning
The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under
The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under
Having two copies of the APOE4 gene may be the genetic cause of up to one fifth of all Alzheimer's disease (AD) cases, a new study suggests.
Two copies of APOE4 may be more than just a risk factor for AD; the pair may cause the disease in 15%-20% of cases.
By: Kelli Whitlock Burton
Having two copies of the APOE4 gene may be the genetic cause of up to one fifth of all Alzheimer’s disease cases, a new study suggests.
The DOJ issued a notice of proposed rulemaking on Thursday, jumpstarting a 60-day public comment period on rescheduling marijuana from Schedule I to Schedule III.
Zurnai, from Purdue, is the first nalmefene hydrochloride auto-injector for known or suspected opioid overdose in people aged 12 years and older.
By: Alicia Ault, Kelli Whitlock Burton
The US Food and Drug Administration (FDA) has declined to approve a treatment that combines the psychedelic drug midomafetamine with assisted therapy (MDMA-AT) for the treatment of posttraumatic stress disorder (PTSD).
(833) 317-6278 
